Several CVOTs with published results have shown a neutral effect on ASCVD for dipeptidyl peptidase-4 (DPP-4) inhibitors compared with placebo when added to standard care for patients with T2DM and high CV risk or established CVD [5–8]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.